Compare Alphabet Inc Class A (GOOGL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Tango Therapeutics Inc. — how do they compare? Alphabet Inc Class A trades at $343 (market cap $4.23T), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Alphabet Inc Class A is far larger — about 1131× Tango Therapeutics Inc.'s market cap, and Alphabet Inc Class A pays a 0.25% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 86 Days and Tango Therapeutics Inc. for 0 Days on average.
| GOOGL | TNGX | |
|---|---|---|
Market Cap | $4.23T | $3.74B |
Volume | 27,871,114 | 3,438,781 |
Sector | Media | Health |
52-Week High | $402.62 | $32.90 |
52-Week Low | $250.46 | $7.50 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $4.12T | $2.76B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $353.78, up 0.3% with strong technical momentum as price approaches resistance at $356. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $9.11 versus $2.87, continuing a pattern of earnings outperformance. Revenue growth accelerated to $402.84 billion in 2025 with net income margins expanding to 32.8%. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $430.96 consensus target, though RSI levels suggest potential near-term overbought conditions.
Alphabet presents a compelling growth story with AI-driven expansion and strong financial execution. The primary investment opportunity lies in continued AI leadership and cloud growth, while risks include antitrust scrutiny and tech sector volatility. With valuation metrics remaining reasonable (P/E 17.75) despite strong performance, the stock offers balanced upside potential for long-term investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
